Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Fate Therapeutics (FATE)

Fate Therapeutics (FATE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Fate Therapeutics 12278 SCRIPPS SUMMIT DRIVE SAN DIEGO CA 92131 USA

www.fatetherapeutics.com P: 858-875-1800

Description:

Fate Therapeutics is a clinical-stage biopharmaceutical company, which is focused on the development of programmed cellular immunotherapies for cancer and immune disorders.' The company uses various therapeutic approaches for cell programming to develop cell therapies. The company programs cells of the blood and immune system, including natural killer (NK) cells, T cells and CD34 cells, and is advancing a pipeline of programmed cellular immunotherapies. It uses pharmacologic modulators, such as small molecules, to enhance the biological properties and therapeutic function of healthy donor-sourced cells ex vivo before the product candidates are administered to a patient. It also uses human induced pluripotent stem cells (iPSCs) to generate a clonal master iPSC line having preferred biological properties and direct the fate of the clonal master iPSC line to create its cell therapy product candidate.

Key Statistics

Overview:

Market Capitalization, $K 545,183
Enterprise Value, $K 503,313
Shares Outstanding, K 113,817
Annual Sales, $ 63,530 K
Annual Net Income, $ -160,930 K
Last Quarter Sales, $ 1,680 K
Last Quarter Net Income, $ -44,120 K
EBIT, $ -190,510 K
EBITDA, $ -176,430 K
60-Month Beta 1.66
% of Insider Shareholders 5.04%
% of Institutional Shareholders 97.54%
Float, K 108,081
% Float 94.96%
Short Volume Ratio 0.51

Growth:

1-Year Return -23.15%
3-Year Return -94.53%
5-Year Return -72.13%
5-Year Revenue Growth 1,240.30%
5-Year Earnings Growth -37.82%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.45 on 02/26/24
Latest Earnings Date 05/01/24
Earnings Per Share ttm -1.64
EPS Growth vs. Prev Qtr 2.17%
EPS Growth vs. Prev Year 22.41%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%

FATE Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -38.17%
Return-on-Assets % -28.42%
Profit Margin % -253.31%
Debt/Equity 0.00
Price/Sales 9.03
Price/Cash Flow N/A
Price/Book 1.35
Book Value/Share 3.74
Interest Coverage -0.98
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar